PubMedCrossRef 34 Martin DR, Ruijne

N, McCallum L, O’Hal

PubMedCrossRef 34. Martin DR, Ruijne

N, McCallum L, O’Hallahan J, Oster P: The VR2 epitope on the PorA p 1.7–2,4 Adriamycin chemical structure protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006,13(4):486–491.PubMedCentralPubMedCrossRef 35. Yazdankhah SP, Kriz P, Tzanakaki G, Kremastinou J, Kalmusova J, Musilek M, Alvestad T, Jolley K, Wilson DJ, McCarthy ND, Caugant DA, Maiden MCJ: Distribution of serogroups and Genotypes among disease associated and carried isolates of Neisseria meningitidis from Czech Republic, Greece and Norway. J Clin Microbiol 2004,42(11):5146–5153.PubMedCentralPubMedCrossRef 36. Yazdankhah SP, Kesanopoulos K, Tzanakaki G, Kremastinou J, Caugant DA: Variable-number tandem repeat analysis of meningococcal isolates belonging to the sequence type 162 complex. J Clin Microbiol 2005,43(9):4865–4867.PubMedCentralPubMedCrossRef PI3K Inhibitor Library purchase 37. Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, Medini D: Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013,31(43):4968–4974.PubMedCrossRef

Mocetinostat cost 38. Fagnocchi L, Biolchi A, Ferlicca F, Boccadifuoco G, Brunelli B, Brier S, Norais N, Chiarot E, Bensi G, Kroll JS, Pizza M, Donnelly J, Giuliani MM, Delany I: Transcriptional Regulation of the nadA Gene in Neisseria meningitidis Impacts the Prediction of Coverage of a Multicomponent Meningococcal Serogroup B Vaccine. Infect Immun 2013,81(2):560–569.PubMedCentralPubMedCrossRef Authors’ contributions GT, MT, MP participated in the study design and the preparation of the manuscript, EH, KK, AX participated in the laboratory experimental work and in the interpretation of data, SB, AM, LO and MC participated in the analysis Adenosine of the data.”
“Background Mycoplasmas are the smallest known self-replicating prokaryotes originally isolated from bovine pleuropneumonia and are

also referred as pleuropneumonia like organisms (PPLO). A key characteristic of mycoplasma is the lack of a cell wall, which allows exchange of different components between the host membrane and the M. pneumoniae membrane after adhesion [1, 2]. M. pneumoniae is a human pathogen that colonizes the ciliated upper and lower respiratory tract, causing atypical pneumonia. M. pneumoniae is also found to be associated with other respiratory tract infections such as tracheobronchitis, bronchiolitis, croup, Acute Respiratory Distress Syndrome (ARDS), Guillain-Barre Syndrome (GBS), stroke and less severe upper respiratory tract infections in older children as well as in young adults [3–7]. Adherence of M. pneumoniae to the human host respiratory epithelium is a prerequisite for the colonization and subsequent induction of disease [4, 8]. It attaches to ciliated epithelial cells in the respiratory tract, where it induces ciliostasis that protects the M.

Comments are closed.